

Taltz Together™ Savings and Support Enrollment Form, and Prescription Information

OFFICE STAFF • Please FAX the FRONT AND BACK of this form with prescriber and patient signature to 1-844-344-8108

• Please call the Taltz Together program at 1-844-TALTZ-NOW (1-844-825-8966) for any questions or concerns

	mation (Must complet		<u>'</u>							
Name (First, Last)			DOB (MM/DD/YYYY)							
US or Puerto Rico	Resident □ Yes □ No	Gender □M □F	Preferred Language ☐ English	□ Spanish □ Oth	ner					
Address			City		State	_ ZIP Code				
Phone*			Email							
*By providing my	mobile telephone number ar	nd signing this form, I agre	e to receive automated [and or prered	corded] calls and texts	s about the Taltz To					
			cts. By signing below, I agree and cert m or have government insurance			edicare Part D, TRICA	ARE, and others.			
☐ I would like to☐ I would like Ta	request a Taltz Savings	Card and agree to the dagree to the	e Savings Card Terms and Cond and Conditions on page 2.							
SIGNATURE OF PATIENT DATE (MM/DD/YYYY)										
2. Primary Pre	scription Information		· ·	,						
☐ Copy of the poli	cyholder's insurance card	(front and back) is attac	hed	insurance informatio	on OR □ No in	surance coverag	е			
Prescription Company Policyholder			Prescription Company Phone							
Policy #		Group #	Rx BIN		PC	N				
3. Support Req	uested for This Patier	nt								
Select the one opt	ion below that your patien	t or office would like to	receive				additional			
☐ Benefits Investigation & Field Reimbursement Support OR ☐ Taltz Together will research the patient's insurance and in-network pharmacy options to help identify the lowest out-of-pocket cost available.			Taltz Together and/or the Lilly Field Reimbursement Manager will work on the patient's behalf if access issues arise after the Taltz prescription is sent to the specialty pharmacy listed above. patient supp □ Injection To □ Sharps Dis □ Sharps Dis □ Container			ion Training s Disposal				
4. Prescriber II	formation									
Name (First, Last)				NPI #						
Practice Name		Address								
CityState		ZIP Code Phone Fax								
Office Contact Name		Office Contact Phone								
					Office Contact Email Group Tax ID #					
Office Contact Em	ail									
Office Contact Em 5. Clinical Info	ail rmation		Group	Tax ID #						
Office Contact Em 5. Clinical Info Primary Diagnos	ail rmation sis/ICD-10 Codes (select	all that apply) □ Plaq	Group ue Psoriasis (ICD-10 Code: L40.0	Tax ID # O) □ Arthropathic	Psoriasis (ICD-1	0 Code: L40.50)				
Office Contact Em 5. Clinical Informary Diagnost Prior Treatment	ail rmation sis/ICD-10 Codes (select Failures, Contraindication	all that apply) □ Plaqı ons, Intolerances, or A	Group ue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply)	Tax ID #	Psoriasis (ICD-1 gic or systemic a	0 Code: L40.50)				
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment Phototherapy	ail rmation sis/ICD-10 Codes (select Failures, Contraindication ☐ Methotrexate ☐ HUMI	all that apply) □ Plaqı ons, Intolerances, or A	Group ue Psoriasis (ICD-10 Code: L40.0	Tax ID #	Psoriasis (ICD-1 gic or systemic a	0 Code: L40.50)				
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment □ Phototherapy 6. Taltz Prescri	mation is/ICD-10 Codes (select Failures, Contraindication Methotrexate □ HUMI ption Information	all that apply) □ Plaq ons, Intolerances, or <i>F</i> RA® □ Otezla® □ El	Group ue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply) NBREL® STELARA® COSE	Tax ID #	Psoriasis (ICD-1 gic or systemic a	0 Code: L40.50) agent				
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment Phototherapy 6. Taltz Prescri Autoinjector	rmation is/ICD-10 Codes (select Failures, Contraindication Methotrexate HUMI ption Information Dosing: Moderate to S	all that apply)	Group ue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply) NBREL® STELARA® COSE or without Psoriatic Arthritis	Tax ID # O) □ Arthropathic □ No previous biolo ENTYX® □ Other(s)	Psoriasis (ICD-1 gic or systemic a	0 Code: L40.50) agent Day Supply	Refills			
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment Phototherapy 6. Taltz Prescri Autoinjector (80 mg/mL) OR	rmation sis/ICD-10 Codes (select Failures, Contraindication Methotrexate HUMI ption Information Dosing: Moderate to S Starting Dose: 16	all that apply)	Group ue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply) NBREL® STELARA® COSE or without Psoriatic Arthritis utaneous injections on Day 1, then	Tax ID # O) □ Arthropathic □ No previous biolo ENTYX® □ Other(s)	Psoriasis (ICD-1 gic or systemic a	0 Code: L40.50) agent				
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment Phototherapy 6. Taltz Prescri Autoinjector (80 mg/mL) OR Prefilled Syringe	rmation sis/ICD-10 Codes (select Failures, Contraindication Methotrexate HUMI ption Information Dosing: Moderate to S Starting Dose: 16 induction dose (1) Induction Dose: 2	all that apply) □ Plaquons, Intolerances, or ARA® □ Otezla® □ Elevere Psoriasis with of Go mg (2 x 80 mg) subcutaneous x 80 mg) 2 weeks later (1 x 80 mg subcutaneous	Group ue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply) NBREL® STELARA® COSE or without Psoriatic Arthritis utaneous injections on Day 1, then week 2) s injection every 2 weeks (weeks 4-	Tax ID #	Psoriasis (ICD-1 gic or systemic a Quantity 3 pens/syringes 2 pens/syringes	O Code: L40.50) agent Day Supply 28 28	Refills 0 1			
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment Phototherapy 6. Taltz Prescri Autoinjector (80 mg/mL) OR	mation sis/ICD-10 Codes (select Failures, Contraindication Methotrexate HUMI ption Information Dosing: Moderate to S Starting Dose: 16 induction dose (1) Induction Dose: 1	all that apply) □ Plaquons, Intolerances, or ARA® □ Otezla® □ Elevere Psoriasis with of 50 mg (2 x 80 mg) subcut x 80 mg) 2 weeks later (1 x 80 mg subcutaneous pose: 1 x 80 mg subcutaneous pose: 1 x 80 mg subcutaneous	Group ue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply) NBREL® STELARA® COSE or without Psoriatic Arthritis utaneous injections on Day 1, then week 2) s injection every 2 weeks (weeks 4- aneous injection (week 12)	Tax ID #	Psoriasis (ICD-1 gic or systemic a Quantity 3 pens/syringes 2 pens/syringes 1 pen/syringe	0 Code: L40.50) agent Day Supply 28 28 28 28	Refills 0			
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment Phototherapy 6. Taltz Prescri Autoinjector (80 mg/mL) OR Prefilled Syringe	rmation sis/ICD-10 Codes (select Failures, Contraindication Methotrexate HUMI ption Information Dosing: Moderate to S Starting Dose: 16 induction dose (1) Induction Dose: 16 Induct	all that apply) □ Plaquons, Intolerances, or ARA® □ Otezla® □ Elevere Psoriasis with of 50 mg (2 x 80 mg) subcut x 80 mg) 2 weeks later (1 x 80 mg subcutaneous pose: 1 x 80 mg subcutaneous pose: 1 x 80 mg subcutaneous	Group ue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply) NBREL® STELARA® COSE or without Psoriatic Arthritis utaneous injections on Day 1, then week 2) s injection every 2 weeks (weeks 4-	Tax ID #	Psoriasis (ICD-1 gic or systemic a Quantity 3 pens/syringes 2 pens/syringes	O Code: L40.50) agent Day Supply 28 28	Refills 0 1			
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment Phototherapy 6. Taltz Prescri Autoinjector (80 mg/mL) OR Prefilled Syringe	mation is/ICD-10 Codes (select Failures, Contraindication Methotrexate HUMI ption Information Dosing: Moderate to S Starting Dose: 16 induction dose (1 x) Induction Dose: 2 Induction Dose: 3 Induction Dose:	all that apply) □ Plaquons, Intolerances, or ARA® □ Otezla® □ Elevere Psoriasis with of 30 mg (2 x 80 mg) subcut x 80 mg 2 weeks later (1 x 80 mg subcutaneous cose: 1 x 80 mg subcutaneous co	Group ue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply) NBREL® STELARA® COSE or without Psoriatic Arthritis utaneous injections on Day 1, then week 2) s injection every 2 weeks (weeks 4- aneous injection (week 12)	Tax ID #	Psoriasis (ICD-1 gic or systemic a Quantity 3 pens/syringes 2 pens/syringes 1 pen/syringe	0 Code: L40.50) agent Day Supply 28 28 28 28	Refills 0 1			
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment Phototherapy 6. Taltz Prescri Autoinjector (80 mg/mL) OR Prefilled Syringe	mation sis/ICD-10 Codes (select Failures, Contraindication Methotrexate HUMI ption Information Dosing: Moderate to S Starting Dose: 16 induction dose (1) Induction Dose: 3 Final Induction Dose: 3 Maintenance Dose OR Dosing: Active Psoriation	all that apply) □ Plaquons, Intolerances, or ARA® □ Otezla® □ Elevere Psoriasis with of 60 mg (2 x 80 mg) subcut x 80 mg) 2 weeks later (1 x 80 mg subcutaneous lose: 1 x 80 mg subcutaneous et 1 x 80 mg subcutaneous fee: 1 x 80	Group ue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply) NBREL® STELARA® COSE or without Psoriatic Arthritis utaneous injections on Day 1, then week 2) s injection every 2 weeks (weeks 4- aneous injection (week 12) eous injection every 4 weeks (there	Tax ID #	Psoriasis (ICD-1 gic or systemic as Quantity 3 pens/syringes 1 pen/syringe	0 Code: L40.50) agent Day Supply 28 28 28 28 28	Refills			
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment Phototherapy 6. Taltz Prescri Autoinjector (80 mg/mL) OR Prefilled Syringe	mation is/ICD-10 Codes (select Failures, Contraindication Methotrexate HUMI ption Information Dosing: Moderate to S Starting Dose: 16 induction dose (1) Induction Dose: 16 Final Induction D Maintenance Dos OR Dosing: Active Psoriation	all that apply) □ Plaquons, Intolerances, or ARA® □ Otezla® □ Elevere Psoriasis with of Somg (2 x 80 mg) subcut x 80 mg) 2 weeks later (1 x 80 mg subcutaneous cose: 1 x 80 mg subcutaneous co	Group Lue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply) NBREL® STELARA® COSE Lor without Psoriatic Arthritis Lataneous injections on Day 1, then week 2) Is injection every 2 weeks (weeks 4- Laneous injection (week 12) Louis injection every 4 weeks (there- Lateral Cost (weeks 4- Lateral Cos	Tax ID #	Psoriasis (ICD-1 gic or systemic as) Quantity 3 pens/syringes 2 pens/syringes 1 pen/syringe 1 pen/syringe	Day Supply 28 28 28 28 Day Supply	Refills			
Office Contact Em 5. Clinical Info Primary Diagnos Prior Treatment Phototherapy 6. Taltz Prescri Autoinjector (80 mg/mL) OR Prefilled Syringe (80 mg/mL) Prescriber Sign	mation sis/ICD-10 Codes (select Failures, Contraindication Methotrexate HUMI ption Information Dosing: Moderate to S Starting Dose: 16 induction Dose: 1 I	all that apply) □ Plaquons, Intolerances, or ARA® □ Otezla® □ Elevere Psoriasis with of 60 mg (2 x 80 mg) subcut x 80 mg) 2 weeks later (1 x 80 mg subcutaneous obse: 1 x 80 mg subcutaneous et arthritis without Mode x 80 mg each (160 mg to se: 1 x 80 mg by subcutaneous et arthritis without Mode x 80 mg each (160 mg to se: 1 x 80 mg by subcutaneous et arthritis without Mode x 80 mg each (160 mg to se: 1 x 80 mg by subcutaneous et arthritis without Mode x 80 mg each (160 mg to se: 1 x 80 mg by subcutaneous et arthritis without Mode x 80 mg each (160 mg to se: 1 x 80 mg by subcutaneous et arthritis without Mode x 80 mg by subcutaneous et arth	Group Lue Psoriasis (ICD-10 Code: L40.0 Allergies (select all that apply) NBREL® STELARA® COSE Lor without Psoriatic Arthritis Lutaneous injections on Day 1, then week 2) s injection every 2 weeks (weeks 4- aneous injection (week 12) Bous injection every 4 weeks (there leverate to Severe Psoriasis cotal) by subcutaneous injection on	Tax ID #	Psoriasis (ICD-1 gic or systemic as Quantity 3 pens/syringes 2 pens/syringe 1 pen/syringe 1 pen/syringe Quantity 2 pens/syringes 1 pen/syringes 1 pen/syringes 1 pen/syringe	0 Code: L40.50) agent Day Supply 28 28 28 28 Day Supply 28 28	Refills			

By signing below, I certify: 1) The therapy is medically necessary and that this information is accurate to the best of my knowledge; 2) I am disclosing this information to Eli Lilly and Company, its affiliates, agents, representatives, business partners, and service providers (together "Lilly") to help enable treatment for this patient; 3) The patient is aware of, has consented to, and has directed my disclosure of their information to Lilly so that Lilly may contact the patient to further enable services for those purposes and that such consent and direction applies to disclosures made through the duration of the patient's therapy; 4) I will not seek reimbursement from any third party for the support Lilly provides; and 5) I am licensed to prescribe the prescription medication identified in this form, the prescription complies with my state-specific prescribing requirements, and I appoint Lilly as my agent for the limited purpose of conveying this prescription to the dispensing pharmacy.

I understand that by signing this form, I am requesting support from Eli Lilly and Company for patients receiving Taltz pursuant to the approved indication.

PRESCRIBER MUST MANUALLY SIGN Rubber stamps, signature by other office personnel for the prescriber, and computer-generated signatures will not be accepted.

PRESCRIBER SIGNATURE (Dispense as written)

DATE (MM/DD/YYYY)

May substitute/brand exchange permitted

PP-RC-US-0880

What to Know About Taltz Together Support

We created the Taltz Together program to give you personalized support while taking Taltz. Through this ongoing support, your Taltz Together team will serve as your dedicated partner. They can help you navigate through insurance processes, identify savings opportunities, and answer questions you may have about Taltz.

Taltz Together Ongoing Support Enrollment Consent

The Ongoing Support Offerings included in Taltz Together provide support after you've received your medication, like check-in calls to answer any questions you might have about Taltz. As part of your participation in the Ongoing Support Offerings, Eli Lilly and Company and Lilly USA, LLC and its affiliates, agents, representatives, and service providers (together "Lilly") may use, disclose, and/or transfer the personal information you supply to provide support related to your condition and treatment to administer the program.

Offerings include:

- · Contacting you by email, mail, or telephone to provide personalized support such as informational and marketing materials
- Responding to customer support requests and/or questions about your treatment
- · Requesting feedback on your experience with the related products, offerings, and programs, including market research
- Disclosing your enrollment and use of this support to your doctors and insurers
- Analyzing and/or measuring program performance for future enhancements
- Other opportunities and activities related to your condition and therapy that are not part of Taltz Together. These activities include opportunities to share your story and participate in studies about products and offerings

By checking the corresponding box on the first page under Section 3: Ongoing Support for Taltz, you consent to your enrollment in Taltz Together Ongoing Support as described in this Consent.

Patient HIPAA Authorization

Before Taltz Together can start helping you, Lilly may ask for some information about you and your health. This is known as your *Protected Health Information*, or *PHI*. By signing this form, you understand and agree that your PHI may be shared or used as explained below.

PHI includes information like:

- Your health insurance or benefits, including how much coverage you have
- All records about your treatment
- Anything that affects your health
- Whether you're staying on your medicine or treatment

If you agree, your PHI may be shared by:

- Your doctors and other healthcare providers
- Your healthcare plan or health insurance company
- Your pharmacy
- Others who might have your PHI

Your PHI is used in ways like these:

- To learn how much of your Lilly treatment is covered by your insurance
- To help you find other ways to afford your treatment
- To track your use of your Lilly treatment
- To share information with your healthcare provider
- To make sure that you receive high-quality services from the program
- To measure program performance and make program improvements
- Internal Lilly use of data to drive business decisions and metrics on hub performance
- Reports to our sales force regarding HCP use of hub services
- Conversations/messages to your HCP regarding trends and hub performance

Other things you should know about sharing and using your PHI:

- We only ask for and share the PHI that we need to provide the benefits you want. We do not ask for any PHI that we do not need, but we may receive some in the health records sent to us
- You don't have to give permission to share your PHI with Lilly to receive treatment from your healthcare providers, your prescription from your pharmacy, or benefits from your healthcare plan, but Taltz Together may not be able to help you without it
- After your PHI has been shared, it may no longer be covered by federal and state privacy laws (such as HIPAA), and it may be shared again
- Your permission to share and use your PHI lasts for 1 year, unless you change your mind before then. You can stop allowing your PHI to be shared at any time, but this will not affect information or disclosures shared before Lilly receives your request
- Your healthcare providers (such as pharmacies) may be paid by us in exchange for sharing your PHI and/or to perform certain services for you. They may use your information to provide services, such as contacting you about Lilly products

If you would like to opt out of the program or make changes to your enrollment:

• You can stop sharing your PHI with us or change what you share by calling us at **1-844-TALTZ-NOW** (1-844-658-6426) or by writing us at PO Box 12307, La Jolla, CA 92039

Savings Card Terms and Conditions

Eligibility Criteria: By using the Taltz Savings Card ("Card"), you attest that you meet the eligibility criteria and will comply with the Terms and Conditions described below:

Offer void where prohibited by law and subject to monthly and annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE/CHAMPUS, or any state patient or pharmaceutical assistance program. If you live in Massachusetts, the Card expires on the earlier of: (i) the expiration date of this card 12/31/2022; (ii) the date an AB-rated generic equivalent for Taltz becomes available; or (iii) June 30, 2019, absent a change in Massachusetts state law. If you live in California, the card expires on the earlier of: (i) the expiration date of this card 12/31/2022 or (ii) the date an FDA-approved therapeutic equivalent for Taltz or over-the-counter product with the same active ingredient becomes available. Available only in the US and Puerto Rico for residents of the US and Puerto Rico.

By accepting this offer, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you should notify your insurance carrier of your redemption of this Card. This offer is not valid with any other program, discount, discount card, incentive, or similar offer involving Taltz. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase or trade; or to counterfeit this Card. This offer may be terminated, rescinded, revoked or amended by Lilly USA, LLC, at any time without notice. Card activation required. This Card is not health insurance. This Card expires on 12/31/2022. Patients must first use their card by 12/31/2019 and are eligible for savings for up to 36 months of therapy. Subject to additional terms and conditions, which can be found at www.taltz.com.

